PL2229185T3 - Łączne podawanie środka związanego z peptydem internalizacji tat ze środkiem przeciwzapalnym - Google Patents
Łączne podawanie środka związanego z peptydem internalizacji tat ze środkiem przeciwzapalnymInfo
- Publication number
- PL2229185T3 PL2229185T3 PL08859906T PL08859906T PL2229185T3 PL 2229185 T3 PL2229185 T3 PL 2229185T3 PL 08859906 T PL08859906 T PL 08859906T PL 08859906 T PL08859906 T PL 08859906T PL 2229185 T3 PL2229185 T3 PL 2229185T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- administration
- internalization peptide
- linked
- tat internalization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99267807P | 2007-12-05 | 2007-12-05 | |
| PCT/US2008/085280 WO2009076105A2 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| EP08859906.3A EP2229185B8 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2229185T3 true PL2229185T3 (pl) | 2016-03-31 |
Family
ID=40756064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08859906T PL2229185T3 (pl) | 2007-12-05 | 2008-12-02 | Łączne podawanie środka związanego z peptydem internalizacji tat ze środkiem przeciwzapalnym |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8080518B2 (pl) |
| EP (1) | EP2229185B8 (pl) |
| JP (1) | JP5520230B2 (pl) |
| CN (1) | CN101970011B (pl) |
| AU (1) | AU2008335490B2 (pl) |
| BR (1) | BRPI0820912B1 (pl) |
| DK (1) | DK2229185T3 (pl) |
| ES (1) | ES2555524T3 (pl) |
| HR (1) | HRP20151312T1 (pl) |
| HU (1) | HUE027216T2 (pl) |
| PL (1) | PL2229185T3 (pl) |
| PT (1) | PT2229185E (pl) |
| SI (1) | SI2229185T1 (pl) |
| WO (1) | WO2009076105A2 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US8685925B2 (en) * | 2006-07-11 | 2014-04-01 | Nono Inc. | Method and compositions for treating stroke with fever |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| DK2307035T3 (da) * | 2008-05-16 | 2014-01-20 | Nono Inc | Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi |
| WO2010028089A2 (en) * | 2008-09-03 | 2010-03-11 | Arbor Vita Corporation | Agents and methods for treatment of pain |
| CN102458441A (zh) | 2009-06-10 | 2012-05-16 | 诺诺公司 | 用于治疗神经疾病的模型系统和治疗方案 |
| WO2011038397A2 (en) * | 2009-09-28 | 2011-03-31 | Duke University | Peptide adjuvants, vaccines, and methods of use |
| WO2011126833A2 (en) * | 2010-03-29 | 2011-10-13 | Massachusetts Institute Of Technology | Anti-inflammatory factors |
| CA2802207C (en) * | 2010-06-10 | 2018-10-30 | Indiana University Research And Technology Corporation | Materials and method for suppressing inflammatory and neuropathic pain |
| CA2807946C (en) * | 2010-08-12 | 2018-09-25 | Nono Inc. | Treatment of penetrative injury to the brain |
| WO2012156308A1 (en) * | 2011-05-13 | 2012-11-22 | Københavns Universitet (University Of Copenhagen) | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain |
| DK2723363T3 (en) | 2011-06-24 | 2018-10-15 | Nono Inc | COMBINATION THERAPY AGAINST CREAM |
| WO2013148366A1 (en) | 2012-03-27 | 2013-10-03 | Duke Unversity | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| EP2925338B8 (en) * | 2012-11-28 | 2019-05-22 | NoNO Inc. | Lyophilized formulation of tat-nr2b9c |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| WO2014150350A1 (en) * | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| ES2600488T3 (es) | 2014-05-23 | 2017-02-09 | Ares Trading S.A. | Composición farmacéutica líquida |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| WO2016049280A1 (en) * | 2014-09-24 | 2016-03-31 | Memorial Sloan Kettering Cancer Center | mTORC1 MODULATION |
| BR112020006321A2 (pt) | 2017-09-30 | 2020-11-17 | Biocells (Beijing) Biotech Co., Ltd. | composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2354700A (en) * | 1998-12-11 | 2000-06-26 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| AU769315B2 (en) * | 1999-08-24 | 2004-01-22 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) * | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| US6887687B2 (en) * | 2001-07-30 | 2005-05-03 | Immunex Corporation | Nucleic acids encoding human ataxin-1-like polypeptide IMX97018 |
| WO2004071531A1 (en) * | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| US7947645B2 (en) * | 2004-09-02 | 2011-05-24 | Cognosci, Inc. | APO E analogs and methods for their use |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| WO2009006611A1 (en) * | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| KR101717275B1 (ko) * | 2007-07-26 | 2017-03-16 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
-
2008
- 2008-11-26 US US12/323,915 patent/US8080518B2/en active Active
- 2008-12-02 ES ES08859906.3T patent/ES2555524T3/es active Active
- 2008-12-02 EP EP08859906.3A patent/EP2229185B8/en active Active
- 2008-12-02 JP JP2010537016A patent/JP5520230B2/ja active Active
- 2008-12-02 AU AU2008335490A patent/AU2008335490B2/en active Active
- 2008-12-02 CN CN2008801261196A patent/CN101970011B/zh active Active
- 2008-12-02 BR BRPI0820912-0A patent/BRPI0820912B1/pt active IP Right Grant
- 2008-12-02 PL PL08859906T patent/PL2229185T3/pl unknown
- 2008-12-02 PT PT88599063T patent/PT2229185E/pt unknown
- 2008-12-02 HU HUE08859906A patent/HUE027216T2/en unknown
- 2008-12-02 WO PCT/US2008/085280 patent/WO2009076105A2/en active Application Filing
- 2008-12-02 DK DK08859906.3T patent/DK2229185T3/en active
- 2008-12-02 SI SI200831555T patent/SI2229185T1/sl unknown
-
2015
- 2015-12-02 HR HRP20151312TT patent/HRP20151312T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2555524T3 (es) | 2016-01-04 |
| DK2229185T3 (en) | 2016-01-11 |
| SI2229185T1 (sl) | 2016-02-29 |
| EP2229185A2 (en) | 2010-09-22 |
| BRPI0820912B1 (pt) | 2022-05-24 |
| EP2229185B1 (en) | 2015-10-07 |
| BRPI0820912A2 (pt) | 2018-07-17 |
| PT2229185E (pt) | 2016-01-26 |
| US20090176713A1 (en) | 2009-07-09 |
| US8080518B2 (en) | 2011-12-20 |
| WO2009076105A2 (en) | 2009-06-18 |
| WO2009076105A3 (en) | 2010-01-07 |
| AU2008335490B2 (en) | 2013-08-22 |
| HRP20151312T1 (hr) | 2016-03-11 |
| JP2011506328A (ja) | 2011-03-03 |
| EP2229185B8 (en) | 2016-12-21 |
| JP5520230B2 (ja) | 2014-06-11 |
| HUE027216T2 (en) | 2016-08-29 |
| AU2008335490A1 (en) | 2009-06-18 |
| CN101970011B (zh) | 2013-04-24 |
| EP2229185A4 (en) | 2011-11-23 |
| CN101970011A (zh) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2229185T3 (pl) | Łączne podawanie środka związanego z peptydem internalizacji tat ze środkiem przeciwzapalnym | |
| HRP20182200T1 (hr) | Nova protuupalna sredstva | |
| EP2440231A4 (en) | CO-ADMINISTRATION OF AN INTERNALIZATION PEPTIDE AGENT WITH ANTI-INFLAMMATORY | |
| IL230542B (en) | Anti-inflammatory factors | |
| ZA201104497B (en) | Peptide therapeutic conjugates and uses thereof | |
| EP2504034A4 (en) | TOPICAL IBUPROFEN FORMULATIONS | |
| EP2403852B8 (en) | 2-aminobenzimidazole-5-carboxamides as anti-inflammatory agents | |
| EP2305307A4 (en) | ANALGESIC ANTI-INFLAMMATORY PREPARATION FOR EXTERNAL APPLICATION | |
| EP2407179A4 (en) | EXTERNAL PREPARATION WITH A PAIN OR AN INFLAMMATORY AGENT | |
| ZA201008727B (en) | Anti-inflammatory agents | |
| EP2473161A4 (en) | TOPICAL FORMULATIONS WITH A STEROID | |
| HK1199217A1 (en) | Topical pharmaceutical composition including active agents | |
| IL210820A0 (en) | Topical anti-inflammatory compositions and uses thereof | |
| PT3417708T (pt) | Administração de ibuprofeno intravenoso | |
| PL2151237T3 (pl) | Kompozycja farmaceutyczna łącząca niesteroidowy środek przeciwzapalny i środek przeciwdrgawkowy | |
| IL216626A0 (en) | Albumin-amyloid peptide conjugates and uses thereof | |
| ZA201200092B (en) | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound | |
| AP2788A (en) | Simalikalactone E and use thereof as a medicament | |
| ZA201208367B (en) | Anti-inflammatory agents | |
| EP2514440A4 (en) | TRANSDERMAL PREPARATION WITH A BASIC INFLAMMATORY MEDIUM | |
| WO2011072138A9 (en) | Therapeutic use of protein-polymer conjugates | |
| AU2009904787A0 (en) | Anti-inflammatory agents | |
| GB0618363D0 (en) | Improved use of anti-inflammatory glucocorticosteroids |